For example, preclinical work has shown that the simultaneous blockade of EGFR and EP4 outperforms the inhibition of EGFR alone in attenuating the tumorigenic cervical cancer cell signaling of mitogen-activated protein kinase (MAPK), cAMP-response element binding protein (CREB), protein kinase B (also called AKT), and glycogen synthase kinase (GSK) [26]. The gene discussed is PTGER4; the disease is cervical cancer.